Anti-CD25 for tumour specific cell depletion
US11873341B2 · kind B2 · utility
0Cited by
5References
22Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 13, 2019 |
| Grant date | Jan 16, 2024 |
| Priority date | — |
| Expiry date | Feb 26, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2015/8518
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: YQCVQGYRALHRGP (150 to 163) or SVCKMTHGKTRWTQP (166 to 180) on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.